%0 Journal Article
%T Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis
%A Hailin Pang
%A Helong Zhang
%A Ning Zhang
%A Xiaobo Gao
%A Yi Jiang
%J Archive of "Therapeutics and Clinical Risk Management".
%D 2019
%R 10.2147/TCRM.S191022
%X Given the increasing use of immune checkpoint inhibitors (ICIs), a concomitant rise in adverse events is inevitable. In a recent Phase III trial of ICIs versus placebo, we found the staggering difference of incidence of fatal adverse events (FAEs). Hence, we should determine the risk of FAEs in ICIs
%K treatment-related mortality
%K immune mediated death
%K immune mediated mortality
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385768/